Tissue methylated DNA markers for sporadic pancreatic cancer are strongly associated with familial and genetically predisposed pancreatic cancer |
| |
| Affiliation: | 1. Division of Gastroenterology & Hepatology, Mayo Clinic, Rochester, MN, USA;2. Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, USA;3. Division of Anatomic Pathology, Mayo Clinic, Rochester, MN, USA;4. Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA;1. Division of Pediatric Gastroenterology and Hepatology, Post Graduate Institute of Medical Education and Research, Chandigarh, India;2. Department of Gastroenterology, Post Graduate Institute of Medical Education and Research, Chandigarh, India;3. Department of Radiodiagnosis, Post Graduate Institute of Medical Education and Research, Chandigarh, India;4. Department of Pediatrics, Post Graduate Institute of Medical Education and Research, Chandigarh, India;1. Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, CA, USA;2. Division of Pediatric Gastroenterology, Hepatology & Nutrition, Lucille Packard Children''s Hospital at Stanford, Stanford, CA, USA;3. Department of Biostatistics, University of Pittsburgh, Pittsburg, PA, USA;4. Nationwide Children''s Hospital, Columbus, OH, USA;5. University of Pittsburgh, School of Dental Medicine, Pittsburg, PA, USA;6. University of Pittsburgh, School of Medicine, Pittsburg, PA, USA;7. Johns Hopkins Medical Institutions, Baltimore, MD, USA;8. Shanghai General Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China;9. The Ohio State University Wexner Medical Center, Columbus, OH, USA |
| |
| Abstract: | High-risk individuals (HRIs) with familial and genetic predisposition to pancreatic ductal adenocarcinoma (PDAC) are eligible for screening. There is no accurate biomarker for detecting early-stage PDAC. We previously demonstrated that a panel of methylated DNA markers (MDMs) accurately detect sporadic PDAC. In this study we compared the distribution of MDMs in DNA extracted from tissue of PDAC cases who carry germline mutations and non-carriers with family history, with control tissue and demonstrate high discrimination like that seen in sporadic PDAC. These results provide scientific rationale for examining plasma MDMs in HRIs with the goal of developing a minimally-invasive early detection test. |
| |
| Keywords: | Pancreatic cancer DNA methylation Biomarker PDAC" },{" #name" :" keyword" ," $" :{" id" :" kwrd0030" }," $$" :[{" #name" :" text" ," _" :" Pancreatic ductal adenocarcinoma MDM" },{" #name" :" keyword" ," $" :{" id" :" kwrd0040" }," $$" :[{" #name" :" text" ," _" :" Methylated DNA marker CA 19-9" },{" #name" :" keyword" ," $" :{" id" :" kwrd0050" }," $$" :[{" #name" :" text" ," _" :" Carbohydrate antigen 19-9 |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
